Kidney fibroblast growth factor 23 does not contribute to elevation of its circulating levels in uremia

Mace, Maria L.; Gravesen, Eva; Nordholm, Anders; Hofman-Bang, Jacob; Secher, Thomas; Olgaard, Klaus; Lewin, Ewa

Published in: Kidney International

DOI: 10.1016/j.kint.2017.01.015

Publication date: 2017

Document version
Publisher's PDF, also known as Version of record

Document license: CC BY-NC-ND

Citation for published version (APA):
Kidney fibroblast growth factor 23 does not contribute to elevation of its circulating levels in uremia

Maria L. Mace1,2, Eva Gravesen2, Anders Nordholm1,2, Jacob Hofman-Bang2, Thomas Secher3, Klaus Olgaard2 and Ewa Lewin1,2

1University of Copenhagen, Nephrological Department B, Herlev Hospital, Herlev, Denmark; 2University of Copenhagen, Nephrological Department P, Rigshospitalet, Copenhagen, Denmark; and 3Gubra, Hoersholm, Denmark

Fibroblast growth factor 23 (FGF23) secreted by osteocytes is a circulating factor essential for phosphate homeostasis. High plasma FGF23 levels are associated with cardiovascular complications and mortality. Increases of plasma FGF23 in uremia antedate high levels of phosphate, suggesting a disrupted feedback regulatory loop or an extra-skeletal source of this phosphatonin. Since induction of FGF23 expression in injured organs has been reported we decided to examine the regulation of FGF23 gene and protein expressions in the kidney and whether kidney-derived FGF23 contributes to the high plasma levels of FGF23 in uremia. FGF23 mRNA was not detected in normal kidneys, but was clearly demonstrated in injured kidneys, already after four hours in obstructive nephropathy and at 8 weeks in the remnant kidney of 5/6 nephrectomized rats. No renal extraction was found in uremic rats in contrast to normal rats. Removal of the remnant kidney had no effect on plasma FGF23 levels. Well-known regulators of FGF23 expression in bone, such as parathyroid hormone, calcitriol, and inhibition of the FGF receptor by PD173074, had no impact on kidney expression of FGF23. Thus, the only direct contribution of the injured kidney to circulating FGF23 levels in uremia appears to be reduced renal extraction of bone-derived FGF23. Kidney-derived FGF23 does not generate high plasma FGF23 levels in uremia and is regulated differently than the corresponding regulation of FGF23 gene expression in bone.

Correspondence: Ewa Lewin, University of Copenhagen, Nephrological Department B, Herlev Hospital, DK 2730 Copenhagen, Denmark. E-mail: ewa.lewin@regionh.dk or lewin@dadlnet.dk

Received 14 June 2016; revised 21 December 2016; accepted 5 January 2017; published online 22 March 2017

Patients with chronic kidney disease (CKD) develop very high plasma levels of fibroblast growth factor 23 (FGF23), an early and important component of their disturbed mineral and bone disorder (MBD).1–3 A large increase in FGF23 is an important factor associated with high risk of morbidity and mortality.4–7 Still, the mechanisms initiating and maintaining the high plasma levels of FGF23 in CKD are poorly understood,8–11 and excessive secretion of FGF23 by the injured kidney has been suggested.12,13 FGF23 is a 32-kDa glycoprotein that activates the fibroblast growth factor receptor (FGFR) in the presence of the required coreceptor α-Klotho.1,14 FGF23 decreases the type II sodium-dependent phosphate (P) cotransporters NaPi2a and NaPi2c in the proximal tubule of the kidney and thereby inhibits P reabsorption.15–18 Furthermore, FGF23 reduces 1,25-dihydroxy vitamin D (1,25vitD) levels by inhibition of the 25-(OH)vitD 1-α-hydroxylase Cyp27b1 and stimulation of the 1,25vitD 24-hydroxylase Cyp24a1.19–21 FGF23 is part of the complex endocrine network maintaining Ca2+ and P homeostasis, and classical negative feedback loops have been demonstrated between FGF23, 1,25vitD, and parathyroid hormone (PTH).19,20,22,23 FGF23 is also regulated by FGFR1-dependent signaling and local factors in bone.24–27 It is currently believed that osteoblasts and osteocytes are the major source of circulating FGF23.28–30 However, recent evidence has partially challenged this view because conditional ablation of FGF23 in bone cells resulted in moderate reduction in circulating FGF23 levels; therefore, other cellular sources may contribute to circulating FGF23.31,32 Furthermore, the FGF23 increase in uremia antedate high plasma levels of P, suggesting a disrupted feedback regulatory loop or an extraskeletal source of this phosphatonin.1,15 The kidney has been proposed as an extraskeletal source of FGF23, because induced expression of FGF23 has recently been demonstrated in injured kidney models of CKD.12,13,33

The purpose of the present experimental study was to examine whether kidney-derived FGF23 contributes to the high plasma levels of FGF23 in CKD. This was undertaken by studying the expression of FGF23 induced in the kidney rudiment of the 5/6 nephrectomy CKD model and in the kidney of a short-term obstructive nephropathy model. The impact of known regulators of FGF23 expression in bone, such as calcitriol, PTH, dietary P load, and FGFR signaling...
was also examined for potential impact on the regulation of FGF23 expression levels in the injured kidney.

RESULTS
Group characteristics
Long-term uremia was induced by 5/6 nephrectomy, and the uremic rats were examined after 8 weeks and compared with age-matched control rats. A subgroup of the uremic rats had their parathyroid glands removed (PTX-uremic rats). Biochemistry of all groups is shown in Table 1.

Induction and regulation of FGF23 expression in the kidney in uremia
The kidney rudiment of the 5/6 nephrectomy model was examined after 8 weeks of uremia. FGF23 gene expression was not detected in kidneys of control rats with normal kidney function, including control rats given calcitriol (Figure 1a). On the contrary, FGF23 mRNA was clearly detected in kidneys of all uremic rats fed a standard or high-phosphate (HP) diet. The presence of FGF23 protein was confirmed by Western blot, with significantly higher protein levels in uremic HP rats (P < 0.05) (Figure 1b and c). The injured kidney’s FGF23 expression was not further stimulated by calcitriol (Figure 1a). However, calcitriol affected the endogenous 1,25vitD regulation by a significant downregulation of the synthesis enzyme Cyp27b1 and upregulation of the degradation enzyme Cyp24a1 (P < 0.05) (Figure 2h and i). An HP diet strongly stimulated the kidney degradation enzyme Cyp24a1 (P < 0.05) (Figure 2h and i). The injured kidney’s FGF23 expression was not further stimulated by calcitriol (Figure 1a). However, calcitriol affected the endogenous 1,25vitD regulation by a significant downregulation of the synthesis enzyme Cyp27b1 and upregulation of the degradation enzyme Cyp24a1 (P < 0.05) (Figure 2h and i). An HP diet strongly stimulated the kidney’s FGF23 expression in uremic rats (P < 0.01) (Figure 1a). It should, however, be noted that the HP diet also caused more severe kidney disease (Table 1). Uremic HP-diet rats had lower expression levels of the genes coding for the proteins constituting the FGF23 receptor complex FGFR1 IIIc and αKlotho and the phosphate cotransporters NaPi2a and NaPi2c (P < 0.01) compared with uremic standard-diet rats and control rats. Cyp27b1 expression was strongly upregulated in uremic HP-diet rats (Figure 2h), consistent with our previous observation of normal circulating calcitriol levels in this model of long-term uremia. Expression of Cyp27b1 was similarly expressed in uremic standard-diet and control rats, along with same Cyp24a1 expression levels (Figure 2h and i).

Importance of PTH in the regulation of FGF23 gene expression in the kidney and bone in uremia
The effect of PTH signaling on the regulation of FGF23 gene expression in kidney and bone was examined in rats that underwent combined parathyroidectomy and 5/6 nephrectomy (PTX-uremic). Expression of FGF23 was induced in the kidney rudiment of PTX-uremic rats to a similar extent as in uremic rats (Figure 3a). Expression of FGF23 was found in all bone samples, where its relative expression was higher than in the injured kidney. The uremic rats had higher bone FGF23 mRNA and plasma FGF23 levels compared with levels in PTX-uremic rats (P < 0.05) (Figure 3b, Table 1).
coreceptor αKlotho was similarly downregulated in both uremic groups (Supplementary Figure S1) but was not detected in bone (data not shown).

Plasma levels of intact FGF23 in the renal artery and vein
In order to examine whether kidney-derived FGF23 contributes to the high circulating level of FGF23 in uremia, the concentration of intact FGF23 (iFGF23) was measured in the renal artery and vein. Control rats had a renal iFGF23 extraction ratio of 0.31 ± 0.04 (Figure 4a). No renal extraction of iFGF23 was found in uremic rats, and we did not find higher iFGF23 levels in the renal vein of uremic rats compared with the renal artery (Figure 4a). To study the importance of the kidney in FGF23 metabolism, acute unilateral nephrectomy (UNX) was performed in normal rats, resulting in an immediate, large iFGF23 rise (P < 0.05). Excision of the kidney rudiment of uremic rats had no effect on the high plasma iFGF23 levels, especially no decrease in plasma iFGF23 after nephrectomy was found (Figure 4b).

FGF receptor signaling
The influence of FGF receptor signaling was examined using a high dose of the FGF receptor inhibitor (FGFRi) PD173074, which within 5 hours gradually decreased plasma iFGF23 levels to approximately one-third of baseline in both uremic and normal rats (P < 0.01) (Figure 5a). Despite stable plasma Ca²⁺ and P in all groups during the study (Supplementary Table S1), FGFRi caused a large increase in PTH levels in both control and uremic rats (P < 0.05 and P < 0.01) (Figure 5b). FGFRi resulted in not only a suppression of plasma iFGF23, but also a downregulation of the bone’s FGF23 expression in both control and uremic rats (P < 0.001) (Figure 5c). FGF23 expression in the kidney remained similar in both FGFRi- and vehicle-treated uremic rats (Figure 5d). The acute administration of FGFRi increased the expression levels of αKlotho mRNA and protein (Figure 6a–c) and concomitantly increased NaPi2a and NaPi2c mRNA in normal rats (P < 0.05), whereas it had no effect on these genes in uremic rats (Figure 6g–j). The protein expression of NaPi2a was not affected by FGFRi (Figure 6h and i). This might be due to the short observation time or to the rapid phosphaturic effect of PTH. Lower plasma levels of Klotho were found in uremic rats. Plasma Klotho was not affected by FGFRi (Figure 6d). FGFRi affected the enzymes involved in 1,25vitD metabolism in both normal and uremic rats, increasing Cyp27 and decreasing Cyp24 mRNA (Figure 6e and f).

Kidney FGF23 correlates to the degree of fibrosis
The kidney FGF23 mRNA levels were negatively associated with gene expressions of the kidney protective markers αKlotho and BMP7, and positively associated with the
Figure 2 | The effect of chronic uremia, calcitriol, and a high-phosphate (HP) diet on kidney expression of the fibroblast growth factor 23 (FGF23) receptor complex and FGF23 target genes. (a) The same expression levels of \( aKlotho \) mRNA were found in control and uremic standard-diet (SD) rats, whereas they were reduced in the uremic HP rats (\( *P < 0.01 \) vs. sham and uremic SD). (b) Kidney Klotho protein shown on a representative Western blot with glyceraldehyde-3-phosphate dehydrogenase (GAPDH) as a reference protein, and (c) a quantitative analysis of the Western blot of kidney Klotho protein. Similar to the lower \( Klotho \) mRNA levels, the protein levels were reduced in the uremic HP rats (control \( n = 5 \), uremic \( n = 6 \); \( *P < 0.05 \)). (d) The sodium-dependent phosphate cotransporter \( NaPi2a \) gene was expressed at the same level in control and uremic SD rats but significantly decreased in uremic HP rats (\( **P < 0.01 \) vs. control and uremic). (e) \( NaPi2a \) protein is shown on a representative Western blot with GAPDH as a reference protein. (f) A quantitative analysis of the Western blot shows a significant (Continued)
fibrosis markers periostin and TGF1b (Supplementary Figures S2 and S3).

Expression of FGF23 detected in obstructive nephropathy
In order to examine whether FGF23 was expressed in the injured kidney tissue in the absence of severe mineral de­rangements and systemic effects of chronic kidney failure, unilateral ureteral obstruction (UUO) was performed. Interest­ingly, minor levels of FGF23 mRNA were already detected after 2 hours of obstruction, with a further significant increase at 4 and 6 hours (Figure 7a). The increased levels persisted for 10 days in the obstructed kidney. FGF23 mRNA was not detected in the contralateral kidney or in the remaining kidney after UNX (Figure 8). Plasma levels of iFGF23 increased significantly after 2 hours of UUO (P < 0.05) (Figure 7) and remained at a higher level for 10 days of observation time (Figure 8). A similar plasma FGF23 increase was found after UNX (Figure 8b). Bone FGF23 mRNA levels were similar among all groups (Figure 8c). There was no change in the expression levels of TGF1b and phosphate transporters for up to 6-hour UUO, but these became downregulated after 1 day of obstruction (Figure 7b–d).

Localization of renal FGF23 mRNA by in situ hybridization
In situ hybridization was performed in order to illustrate which cells were expressing FGF23 in the kidney. In both the obstructed kidneys and the kidney rudiments of long-term uremic rats, cells within the interstitial space were expressing FGF23 mRNA. In 6-hour UUO, positive FGF23 cells were found in the cortex, medulla, and papilla (Figure 9), which supported the high expression levels found by polymerase chain reaction (Figure 7). The results of immunohistochemistry are discussed in the Supplementary Figure S5.

DISCUSSION
In the present study we demonstrated significant expression of FGF23 in the injured kidney tissue of the 5/6 nephrectomy CKD model and in obstructive nephropathy in rats. Measurements of iFGF23 in the renal artery and vein demonstrated that kidney-derived FGF23 is not generating the high plasma levels of iFGF23 in uremia. The relative gene expression of FGF23 was lower in the kidney compared with bone, supporting the notion of bone being the primary source of FGF23 in CKD. The well-known stimulators of FGF23 expression in bone such as 1,25vitD and PTH did not affect the regulation of FGF23 gene expression in the injured kidney. Inhibition of the FGF receptor resulted in a downregulation of bone FGF23, but it had no effect on the kidney’s FGF23 gene expression. A high dietary P load was, however, associated with significantly increased kidney FGF23 expression, although these rats also became more uremic and had further increased markers of fibrosis.

We have previously demonstrated a significant extraction of FGF23 in the normal kidney and a short half-life of FGF23 of 4 minutes in normal rats.10 In the kidney rudiment of the uremic rat no extraction of FGF23 was found, supporting our earlier findings of a significant prolonged half-life of FGF23 after bilateral nephrectomy and illustrating an
FGF23 levels as control rats. Uremic rats had ten-fold higher plasma FGF23, and removal of the remnant kidney tissue did not result in a drop in FGF23 plasma. Collectively, these results illustrate that kidney-derived FGF23 is not contributing significantly to the high plasma levels of FGF23 in uremia.

Although significant FGF23 expression in injured kidney has been reported by different investigators, the intrarenal localization of FGF23 is still controversial. In the present study, in situ hybridization clearly demonstrated that the main sites of FGF23 mRNA were exclusively in cells within the interstitial space of both the obstructed kidney and kidney rudiment of uremic rats. This is in contrast to other investigations reporting that FGF23 protein was predominantly expressed in tubular cells by immunostaining. Zanchi et al. found focal expression of FGF23 in both proximal and distal tubules in a model of diabetic nephropathy. Expression of FGF23 was detected when the rats had developed proteinuria and early kidney injury but did not coincide with higher plasma levels of FGF23. Spichtig et al. described expression of FGF23 in the cells lining the cysts in a mouse model and in a rat model of polycystic kidney disease before a rise in plasma creatinine and urea. This was associated with an increase in plasma FGF23, while FGF23 mRNA levels in bone remained unchanged. We demonstrated FGF23 protein using Western blot and found significant bands in the kidney tissue of uremic rats and no or minimal protein detected in control rats. The latter could be due to FGF23 protein in capillaries and bound in receptors. We also demonstrated a very early expression of kidney FGF23 gene at 4 and 6 hours of obstructive nephropathy. Collectively, all studies illustrate that the injured kidney expresses FGF23 regardless of the kidney disease model. Further investigations are needed to better characterize these cells localized in the interstitial space expressing FGF23.

Similar expression of FGF23 was found in the injured kidneys of PTX-uremic rats and uremic rats with intact parathyroids. There was no increase in iFGF23 plasma levels and bone expression in PTX-uremic rats. Lavi-Moshayoff et al. have previously demonstrated an important impact of hyperparathyroidism on the development of the high levels of FGF23 in uremia. In the present investigation we found no impact of PTH on the kidney's FGF23 expression. 1,25vitD is a strong stimulus for FGF23 expression in bone. In the present study, no effect of calcitriol was found on the kidney's FGF23 expression, although it cannot be excluded that calcitriol administration might affect kidney FGF23 via its impact on endogenous 1,25vitD metabolism. As such, our results demonstrate that kidney FGF23 is expressed independently of the classical regulatory feedback loops.

FGFR1 signaling has emerged as an important pathway by which FGF23 is regulated in bone. In the present investigation, inhibition of the FGF receptor resulted already after 5 hours in a suppression of FGF23 expression in bone in both control and uremic rats, along with decreased plasma levels. In contrast to this effect on bone, FGFR1 had no effect.

Figure 4 | Plasma levels of intact fibroblast growth factor 23 (FGF23) in the renal artery and vein of normal and uremic rats, and circulating FGF23 levels before and after acute nephrectomy. (a) Concentration of intact FGF23 (iFGF23) in the renal artery and isolated renal vein of long-term uremic rats and age-matched control rats. Control rats had a significant difference in iFGF23 levels between the renal artery and vein, with a 0.31 ± 0.04 renal extraction ratio (**P < 0.01). In uremic rats the iFGF23 levels were significantly higher (P < 0.01), but no significant renal extraction was found (uremic rats n = 9; control rats n = 6). (b) The effect of acute unilateral nephrectomy (UNX) in control rats or removal of the kidney rudiment (NX) in the uremic rats on iFGF23 levels. Acute UNX in control rats resulted in an immediate significant increase in iFGF23 (**P < 0.01) 15 minutes after UNX. NX in uremic rats did not change the plasma levels of iFGF23. Control and uremic rats n = 6.

essential function of the kidney in FGF23 metabolism. The increase in plasma FGF23 levels after ureter obstruction underlines the impact of renal extraction of the hormone on its circulating levels. Noticeably, FGF23 levels were not higher in the renal vein compared with the renal artery in uremic rats, as would have been expected if the kidney were a major contributor to circulating levels. Even though the uremic and PTX-uremic rats had the same expression of FGF23 in their injured kidneys, the PTX-uremic rats had the same plasma
on the kidney’s expression of FGF23, demonstrating again that the kidney’s expression of FGF23 is not regulated in a manner similar to the corresponding expression in bone.

It was shown that FGFRi, despite stable Ca\(^{2+}\) and P, triggered a large increase in PTH in both control and uremic rats. This could be explained by abolition of a suppressive tonus of FGF23 on the parathyroids,\(^36\) although this would be in contrast to the notion of parathyroid resistance to FGF23 in uremia.\(^37\)–\(^39\) Our results demonstrate a relative renal resistance to FGF23 in uremia, as FGFRi did not increase \(\alpha\)Klotho, \(NaPi2a\), and \(NaPi2c\) expression in uremic rats in contrast to the increase seen in normal rats. FGFR1 and perhaps FGFR4 have key roles in FGF23 bioactivity in the kidney.\(^14\) Thus, the lack of response of \(NaPi2a\) and \(NaPi2c\) expression to FGFRi in uremic rats might be due to the fact that FGFR1 expression was already decreased in advance, as shown in our results.

The demonstration in the present study of an increased expression of \(\alpha\)Klotho in the kidney of FGFRi rats is novel. In another investigation of transgenic mice overexpressing FGF23, renal \(\alpha\)Klotho was the most decreased transcript, which together with our results indicates an impact of the FGF23-FGFR pathway on Klotho regulation in the kidney.\(^40\) This is in accordance to conditions described in the parathyroid, where FGF23 was found to inhibit \(\alpha\)Klotho mRNA.\(^36\)

A high phosphate load stimulated FGF23 expression in the injured kidney, plausibly an adaptive mechanism in response to higher phosphate filtration in the functioning nephrons. We were, however, unable to differentiate between a possible adaptive response and a cytotoxic effect of phosphate overload, because the uremic HP rats suffered from more severe uremia with significant downregulation of the FGF23 receptor complex and target genes compared with uremic SD rats. Present results clearly showed expression of the FGF23 gene

---

Figure 5 | Effect of fibroblast growth factor receptor inhibition (FGFRi) on plasma levels of intact fibroblast growth factor 23 (p-iFGF23) and parathyroid hormone (p-PTH), and on the gene expression of FGF23 in bone and kidney in normal and uremic rats. (a) The p-iFGF23 after a single 20-mg dose of PD173074, the pharmacological FGF receptor inhibitor (FGFRi), or vehicle administered at 0 hours (h). FGFRi significantly decreased the p-iFGF23 level after 5 hours to one-third of baseline values in both control and uremic rats (**\(P\) < 0.01). The p-iFGF23 levels were stable in the vehicle-treated groups. (b) FGFRi resulted in a significantly large increase in p-PTH in both control and uremic rats (*\(P\) < 0.05, **\(P\) < 0.01, vs. vehicle groups) as measured after 5 hours. PTH remained stable in vehicle groups. Plasma Ca\(^{2+}\) and P remained stable during the study in all groups (Supplementary Table S1). (c) FGFRi suppressed FGF23 expression in bone in both control and uremic rats (**\(P\) < 0.001 vs. vehicle). (d) No expression of FGF23 was detected in the kidneys of control rats. Similar levels of kidney FGF23 mRNA were found in uremic rats treated with vehicle versus FGFRi. Kidney FGF23 mRNA is shown as the ratio to the mean of reference genes GAPDH and EEF1A1, and Arbp. Bone FGF23 mRNA is shown as the ratio to the mean of reference genes B2M, EEF1A1, and Arbp. Bone FGF23 mRNA is shown as the ratio to the mean of reference genes GAPDH and EEF1A1. Control vehicle and FGFRi \(n = 6\), uremic vehicle \(n = 8\), and uremic FGFRi \(n = 10\).
Figure 6 | Effect of fibroblast growth factor receptor inhibition (FGFRi) on the expression of fibroblast growth factor 23 (FGF23) coreceptor Klotho and FGF23 target genes in kidneys of normal and uremic rats. The FGFR inhibitor (FGFRi) PD173074 or the vehicle was administered to control and uremic rats. (a) The uremic rats had lower expression of αKlotho versus control rats (*P < 0.05). FGFRi increased the expression levels of αKlotho in normal rats (n = 5 vehicle, n = 6 FGFRi; *P < 0.05). (b) Western blot showing kidney Klotho protein expression in control rats given vehicle or FGFRi. A quantitative analysis of the Western blot showed that FGFRi increased the expression levels of Klotho protein in normal rats (n = 6 vehicle, n = 6 FGFRi; *P < 0.05). (c) Western blot showing kidney Klotho protein expression in uremic rats given vehicle or FGFRi. A quantitative analysis showed that FGFRi had no effect on levels of Klotho protein in uremic rats (n = 5 vehicle, n = 6 FGFRi). (d) Plasma Klotho levels were significantly lower (*P < 0.05) in uremic rats but were not affected by FGFRi in these short-duration experiments. (e,f) FGFRi upregulated Cyp27b1 gene expression in both control and uremic rats (***P < 0.01), whereas Cyp24a1 gene expression was significantly downregulated in both uremic and control rat kidneys (*P < 0.05; **P < 0.01). (g,j) The sodium-dependent phosphate cotransporter NaPi2a and NaPi2c genes were downregulated in uremic rats compared with the control group (*P < 0.05). FGFRi increased the expression levels of NaPi2a and NaPi2c in normal rats but had no effect on these genes in uremic rats. (h,i) In contrast to the gene expression, the protein levels in both control and uremic rat kidneys were not affected by FGFRi. All mRNA levels are shown as the ratio to the mean of reference genes B2M, Arbp, and EEF1A1. Control vehicle and FGFRi n = 6, uremic vehicle n = 8, and uremic FGFRi n = 10. To optimize viewing of this image, please see the online version of this article at www.kidney-international.org.
early in the obstructive nephropathy model, but this increase was not associated with any change in NaPi2a and NaPi2c, and therefore these data do not point toward a direct effect of renal FGF23 on phosphate excretion. Because FGF23-expressing cells were located in the interstitium, this further supports no direct relation to FGF23-dependent enzyme and transporters. Furthermore, regulators of renal phosphate excretion and calcitriol homeostasis such as PTH, FGF23, and calcitriol did not regulate renal FGF23 expression. Collectively, these results do not support the notion of renal FGF23 having a direct effect on phosphate transporters or calcitriol regulating enzymes. The kidney’s expression level of FGF23 correlated with the degree of fibrosis based on expression of periostin, and correlated negatively with the kidney protecting factors BMP7 and aKlotho. It therefore seems likely that the kidney’s expression of FGF23 increases with progression of renal fibrosis, but whether FGF23 plays a role in regeneration or in a profibrotic process remains to be established.

Induction of FGF23 expression might take place in other injured organs as well as in tumors. Ischemia of the heart resulted in an increased expression of FGF23 in cardiomyocytes and cardiac fibroblast cells. Expression of FGF23 in injured liver tissue coincided with higher plasma FGF23. FGF23 is expressed in both heart and liver during embryogenesis up to week 8. FGF9 and FGF20 play an important role in nephrogenesis, whereas FGF23 expression was not found in the developing zebrafish kidney. FGF23 belongs to the family of fibroblast growth factors, in which the majority of proteins regulate embryogenesis, growth, and angiogenesis and play an important role in organ regeneration and repair. Whether kidney-derived FGF23 has an autocrine or paracrine function in the renal repair system merits further study. Inflammatory activation of macrophages

Figure 7 | Expression of kidney FGF23, aKlotho, NaPi2a, and NaPi2c genes and plasma fibroblast growth factor 23 (FGF23) levels in early obstructive nephropathy. A unilateral ureter obstruction (UUO) model was used. (a) Normal kidney tissue had no detectable FGF23 gene expression. Minor FGF23 expression was detected after 2-hour (h) UUO, and significant levels were detected at 4 h of UUO, with a further increase at 6 h (P < 0.001). (b–d) The expressions of kidney aKlotho, NaPi2a, and NaPi2c genes remained unchanged at 2, 4, and 6 h of UUO but decreased significantly (P < 0.01) after 24 h of obstruction. (e) Plasma FGF23 increased significantly (P < 0.05) after 2-h UUO to the level we have previously shown in a single-kidney rat model. Kidney FGF23 mRNA is shown as the ratio to reference genes actin, B2M, and TBP. Kidney aKlotho, NaPi2a, and NaPi2c are shown as the ratio to baseline (set to 1); n = 6 in each group.
and bone marrow dendritic cells induce expression of FGF23, and FGF23 has been shown to stimulate expression of tumor necrosis factor alpha in a macrophage cell line. The mechanisms inducing FGF23 expression and its function in these cells and injured tissues are unknown. Even though the phosphaturic and 1,25vitD regulatory functions of FGF23 are clearly established, additional functions of the protein in the inflammatory process are possible.

In conclusion, FGF23 mRNA is not expressed in the normal kidney but is rapidly induced in injured kidneys. The regulation of kidney FGF23 mRNA expression is different from that of its corresponding expression in bone. Kidney-derived FGF23 is not generating the high FGF23 plasma levels in uremia.

METHODS

Animals

Adult male Wistar rats (Taconic A/S, Ejby, Denmark) were used in this study. They were housed in a temperature-controlled environment with a 12-hour light-dark cycle and free access to water and food. The standard diet contained 0.9% Ca, 0.7% P, and 600 IU vitamin D3 per kg food. The HP diet contained 0.9% Ca, 1.4% P, and 600 IU vitamin D3 per kg food (Altromin, Lage, Germany). The biochemistry of rats given calcitriol and HP has been described previously. In long-term studies, all uremic rats were fed an HP diet.

Study approval

The experimental protocols were approved by the Danish Animal Experiments Inspectorate (2012-DY-2934-00023/BES) and performed in accordance with national guidelines.

Experimental protocols

CKD was induced by 1-step 5/6 nephrectomy. Duration of uremia was 8 weeks (renal artery and vein sampling were performed after 14 weeks of uremia). UUO was performed by ligation of the left ureter. UNX was performed by ligation of the renal vessel and removal of the kidney. A group of rats had their parathyroid glands removed by excision under stereomicroscope. Rats were anesthetized with fentanyl/fluanisone and midazolam for the surgical procedures and received carprofen as pain relief. Pento-barbital was used at killing.

The renal artery was punctured close to its junction with the aorta. The renal vein was punctured after prior ligation of the adrenals, testicular veins, and clamping of the vena cava inferior. The aorta was punctured 15 minutes after UNX or NX.

A single 200-ng dose of calcitriol (Leo Pharma, Ballerup, Denmark) was given i.p., and the kidney was harvested after 24 hours. The impact of FGFR signaling was studied using a single 20-mg dose of the pan-FGFR inhibitor PD173074 (LC Laboratories, Woburn, MA) dissolved in 200 μl 96% ethanol administered by oral gavage.

Biochemistry

Plasma Ca2+ was measured at actual pH by ABL 505 (Radiometer, Brønshøj, Denmark). Plasma P, creatinine, and urea were analyzed by levels are shown as the ratio to the mean of reference genes B2M and EEF1A1 (in all groups, 1- to 4-day UUO n = 6, 10-day UUO n = 7, and 10-day UNX n = 5).
Vitros 250 (Ortho-Clinical Diagnostics, Raritan, NJ). PTH levels were measured using rat bioactive intact PTH enzyme-linked immunosorbent assay (Immutopics, San Diego, CA). FGF23 was measured using an intact FGF23 enzyme-linked immunosorbent assay (Kainos Laboratories, Tokyo, Japan). Klotho plasma levels were measured by the O’Brien Kidney Research Core Centre (University of Texas Southwestern, Dallas, TX) using a synthetic Klotho antibody.

Western blot
Protein was extracted using T-PER (Thermo Fisher Scientific, Waltham, MA), and 50 μg of it was loaded on stain-free precast Bio-Rad 4% to 15% gels, transferred onto nitrocellulose Bio-Rad (Hercules, CA) membrane, and blocked in 5% bovine serum albumin in Tris-buffered saline with Tween 20 0.1% (Bio-Rad). Primary FGF23 and Klotho antibody (AB56326, AB154163; Abcam, Cambridge, UK) were diluted in 3% bovine serum albumin 1:1000. NaPi2a (NPB2-13328; Novus Biologicals, Littleton, CO) 1:250 and glyceraldehyde-3-phosphate dehydrogenase antibody (MAB374; Merck Millipore, Billerica, MA) were diluted in milk 1:500. Secondary antibodies were anti-goat, anti-rabbit and anti-mouse (P0160, P0448, and P0447; Dako, Santa Clara, CA). Recombinant FGF23 (PeproTech, Rocky Hill, NJ) was used as a positive control. Quantitative analysis was performed using AlphaEaseFC v.6 (Alpha Innotech, San Leandro, CA).

Quantitative polymerase chain reaction
The kidney and femur (after removal of bone marrow) total RNA were extracted using the EZNA RNA isolation kit (Omega Bio-tek,
Norcross, GA). Synthesis of cDNA was performed using Superscript III (Invitrogen Corp, Waltham, MA). Roche LightCycler 480 (Roche, Basel, Switzerland) was used with a temperature profile of 94°C for 2 minutes, 45 cycles of 94°C for 30 seconds, 59°C for 45 seconds, and 72°C for 90 seconds. The mRNA levels were normalized to the mean of reference genes. Reference gene stability was confirmed using geNorm.62 Primers are listed in Supplementary Table S2.

**In situ hybridization**

Kidneys were fixed in 10% neutral buffered formalin and embedded in blocks of paraffin. In situ hybridization was carried out on 5-μm thick kidney sections using the RNAscope 2.5 HD RED assay (Advanced Cell Diagnostics, Hayward, CA) according to the manufacturer’s instructions. FGF23 was detected with a rat-specific probe against the sequence 9-652 of the mRNA (catalog no. 484301, accession no. NM_130754.1). A probe against the housekeeping gene peptidylprolyl isomerase B (catalog no. 313921, accession no. NM_022563.2) was used as a positive control to verify mRNA quality and assay procedures. A probe targeting the bacterial gene dapB (catalog no. 310043, accession no. EF191515) was used as a negative control.

**Statistical analyses**

Data are expressed as means ± SEM or range. Statistical significance was tested using a 2-tailed t-test for data with normal distribution and the Mann-Whitney U test as a nonparametric test. Linear regression and curve fitting was calculated in GraphPad Prism 4.0. The significance level was set at \( P \leq 0.05 \).

**DISCLOSURE**

All the authors declared no competing interests.

**ACKNOWLEDGMENTS**

The authors would like to thank technician Nina Sejthen. The O’Brien Kidney Research Core Center at the University of Texas Southwestern (P30DK079328) is acknowledged for measuring plasma Klotho. This research was supported by grants from the Lundbeck Foundation (grant number R126-2012-12320), the Kirsten and Freddy Johansen Foundation, the University of Copenhagen, the Waagen Foundation, and the Bjoernow Foundation.

**SUPPLEMENTARY MATERIAL**

Table S1. Plasma calcium and phosphate levels at baseline and 5 hours after administration of FGF receptor inhibitor (FGFR1) or vehicle in normal and uremic rats.

Table S2. Primers.

**Table S1.** Plasma calcium and phosphate levels at baseline and 5 hours after administration of FGF receptor inhibitor (FGFR1) or vehicle in normal and uremic rats.

<table>
<thead>
<tr>
<th>Table S1.</th>
<th>Plasma calcium²⁺ and phosphate levels at baseline and 5 hours after administration of FGF receptor inhibitor (FGFR1) or vehicle in normal and uremic rats.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Normal (n=6)</td>
<td>Uremic (n=6)</td>
</tr>
<tr>
<td>Calcium (mg/dL)</td>
<td>9.3 ± 0.2</td>
</tr>
<tr>
<td>Phosphate (mg/dL)</td>
<td>4.2 ± 0.2</td>
</tr>
</tbody>
</table>

**Table S2.** Primers.

**Table S2.** Primers.

**REFERENCES**


